The present invention provides minimally invasive subdural evacuating systems and methods of use thereof. The subdural evacuating systems include a cutting component and a rod component, wherein the rod component provides an external physical indicator that the surface of the dura mater has been reached, permitting the cutting component to accurately pierce the dura mater with minimal to no risk of damaging any adjacent anatomy.
A stent graft system includes a primary body having a proximal end, a distal end, a first tubular graft material and multiple stents attached to the first tubular graft material. A first branch has a second tubular graft material forming a first branch lumen. The first branch traverses a first fenestration configured in the primary body with a first wire loaded therethrough. A second branch has a third tubular graft material and a second branch lumen. The second branch traverses a second fenestration configured in the primary body with a second wire loaded therethrough. A third branch has a fourth tubular graft material and a third branch lumen. The third branch traverses a third fenestration configured in the primary body with a third wire loaded therethrough. A method for placing a stent graft system is also described.
A61F 2/954 - Instruments spécialement adaptés pour insérer ou retirer les stents ou les endoprothèses déployables couvertes pour insérer les stents ou les endoprothèses déployables couvertes dans une bifurcation
A61F 2/966 - Instruments spécialement adaptés pour insérer ou retirer les stents ou les endoprothèses déployables couvertes possédant une gaine extérieure avec un mouvement longitudinal relatif entre la gaine extérieure et la prothèse, p. ex. utilisant une tige poussoir
A61F 2/958 - Instruments spécialement adaptés pour insérer ou retirer les stents ou les endoprothèses déployables couvertes ballons gonflables pour insérer les stents ou les endoprothèses déployables couvertes
3.
GLYCOPROTEIN A REPETITIONS PREDOMINANT (GARP)-BINDING ANTIBODIES AND USES THEREOF
Isolated or recombinant monoclonal antibodies that bind to GARP are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. Further provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of an anti-platelet agent and a T cell therapy.
The present invention provides compositions and methods for treatment or prevention of tumor growth, fibrosis, acute lung injury or a combination thereof. In one embodiment, the composition comprises a peptide derived from the C-terminal region of endostatin.
Transcranial auricular vagus nerve stimulation apparatus; baby bottles sleeves that include a trigger for use with transcranial auricular vagus nerve stimulation apparatus.
6.
BIOMARKERS TO DETECT RISK OF SINUSOIDAL OBSTRUCTION SYNDROME
The present disclosure provides biomarker panels for evaluating subjects at risk of sinusoidal obstruction syndrome (SOS) early after hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure relates to the use of ST2. L-Ficolin, and HA for prognosing, diagnosing, and/or treating SOS.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 31/7084 - Composés ayant deux nucléosides ou nucléotides, p. ex. dinucléotide de la nicotinamide-adénine, dinucléotide de la flavine-adénine
A61K 38/36 - Facteurs de coagulation sanguine ou de fibrinolyse
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
The present invention provides articulating expandable devices and insertion tools for deploying the articulating expandable devices. The articulating expandable devices are capable of being inserted into narrow spaces and turning around corners. The articulating expandable devices are capable of increasing in height and width when expanded from a closed configuration to an open configuration to occupy a larger volume and to present a larger surface area. The articulating expandable devices are lockable and are capable of rigidly occupying a space after expansion. In some embodiments, the articulating expandable devices are useful as interbody devices for spinal fusions.
The present invention provides expandable devices and insertion tools for deploying the expandable devices. The expandable devices are capable of increasing in height and width when expanded from a closed configuration to an open configuration to occupy a larger volume and to present a larger surface area. The expandable devices are lockable and are capable of rigidly occupying a space after expansion. In some embodiments, the expandable devices are useful as interbody devices for spinal fusions.
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
A composition comprising a plurality of cell aggregates for use in the production of engineered organotypic tissue by organ printing. A method of making a plurality of cell aggregates comprises centrifuging a cell suspension to form a pellet, extruding the pellet through an orifice, and cutting the extruded pellet into pieces. Apparatus for making cell aggregates comprises an extrusion system and a cutting system. In a method of organ printing, a plurality of cell aggregates are embedded in a polymeric or gel matrix and allowed to fuse to form a desired three-dimensional tissue structure. An intermediate product comprises at least one layer of matrix and a plurality of cell aggregates embedded therein in a predetermined pattern. Modeling methods predict the structural evolution of fusing cell aggregates for combinations of cell type, matrix, and embedding patterns to enable selection of organ printing processes parameters for use in producing an engineered tissue having a desired three-dimensional structure.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
B29C 64/112 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant des gouttelettes individuelles, p. ex. de buses de jet
C12M 1/36 - Appareillage pour l'enzymologie ou la microbiologie comportant une commande sensible au temps ou aux conditions du milieu, p. ex. fermenteurs commandés automatiquement
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
Described herein are exemplary embodiments of implantable therapeutic and/or preventative delivering devices that can be composed of one or more layers of a collage- alginate hydrogel and uses thereof.
A61B 17/56 - Instruments ou procédés chirurgicaux pour le traitement des os ou des articulationsDispositifs spécialement adaptés à cet effet
A61B 17/58 - Instruments ou procédés chirurgicaux pour le traitement des os ou des articulationsDispositifs spécialement adaptés à cet effet pour ostéosynthèse, p. ex. plaques, vis ou matériels de fixation
A61M 31/00 - Dispositifs pour l'introduction ou la rétention d'agents, p. ex. de remèdes, dans les cavités du corps
A61B 17/70 - Dispositifs de mise en position ou de stabilisation de la colonne vertébrale, p. ex. stabilisateurs comprenant un liquide de remplissage dans un implant
12.
CD38-NAD+ REGULATED METABOLIC AXIS IN ANTI-TUMOR IMMUNOTHERAPY
The present disclosure provides methods of producing hybrid Th1/Th17 cells. Also provided herein are methods of treating cancer comprising targeting the CD38-mediated metabolic axis.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
13.
SUPERANTIGEN VACCINE CONJUGATE FOR THE TREATMENT OF CANCER
The present disclosure provides compositions comprising vaccine conjugates with a SMEZ-2 carrier. Further provided are methods for treating cancer comprising administering the vaccine conjugates provided herein.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
C07K 14/315 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Streptococcus (G), p. ex. Enterocoques
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The present invention is generally related to compositions comprising and methods of using an optimized peptide delivery system for delivery of an agent into a desired cell. In certain aspects, the agent is a bioactive agent and the methods comprise the treatment or prevention of one or more disease or disorder.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
16.
COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES
Compounds and methods are provided for the treatment of neurological or mitochondrial diseases, including epilepsy. In some embodiments, the compounds are substituted 1,4-naphthoquinones.
A61K 31/136 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p. ex. benzène-amine
A device for measuring eye movement in a human subject comprises a housing, at least one stimulator mounted to the housing, and a sensor. The at least one stimulator is configured to provide stimulus to one or both eyes of the subject. The sensor is configured to collect information related to movement of one or both eyes of the subject. The device also includes a user interface that is configured to control the at least one stimulator and display information collected by the camera.
A61B 3/113 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour déterminer ou enregistrer le mouvement de l'œil
A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p. ex. tremblement de la tête ou des mains ou mobilité d'un membre
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/398 - Électrooculographie [EOG], p. ex. pour la détection du nystagmusÉlectrorétinographie [ERG]
A61B 3/00 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux
A61B 3/11 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour mesurer la distance interpupillaire ou le diamètre de la pupille
A61B 3/14 - Dispositions spécialement adaptées à la photographie de l'œil
18.
Recombinant Fusion Proteins Targeting P-selectin, and Methods of Use Thereof for Treating Diseases and Disorders
The United States Government as Represented by the Department of Veterans Affairs (USA)
Universitat De Barcelona (Espagne)
Inventeur(s)
Tomlinson, Stephen
Alawieh, Ali
Engel, Pablo
Abrégé
The present invention describes compositions and methods for targeting complement inhibition to sites of p-selectin expression, and compositions for inhibiting p-selectin and complement.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
19.
MOTION-ACTIVATED, CLOSED-LOOP NON-INVASIVE VAGUS NERVE STIMULATION FOR NEUROREHABILITATION
A system for neurorehabilitation is disclosed that includes a motion detector configured to generate a motion detection feedback signal, a transcutaneous auricular vagus nerve stimulation module, and a controller configured to receive the motion detection feedback signal and send a stimulation signal to the transcutaneous auricular vagus nerve stimulation module based on the motion detection feedback signal meeting a minimum threshold criteria. A method for neurorehabilitation is disclosed that includes the steps of detecting patient motor activity, determining if the detected patient motor activity meets a minimum threshold criteria, and stimulating a vagus nerve through transcutaneous auricular vagus nerve stimulation if the minimum threshold criteria is met.
A61N 1/32 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
21.
DEVICE, SYSTEM AND METHOD FOR MONITORING NEUROLOGICAL FUNCTIONAL STATUS
A device for measuring eyelid movement in a human subject comprises a housing, at least one stimulator mounted to the housing, and a camera. The at least one stimulator is configured to provide stimulus to one or both eyes of the subject. The camera is configured to collect information related to movement of one or both eyes of the subject. The device also includes a user interface that is configured to control the at least one stimulator and display information collected by the camera.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/16 - Dispositifs pour la psychotechnieTest des temps de réaction
G16H 40/67 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement à distance
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 20/70 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mentales, p. ex. la thérapie psychologique ou le training autogène
A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p. ex. tremblement de la tête ou des mains ou mobilité d'un membre
Provided is an improved breast tissue marker and localization system and method of use. The breast tissue marker and localization system comprising a biocompatible marker and a detector. The biocompatible markers comprise a polymeric binder and a magnetically susceptible material such as an iron oxide nanoparticle wherein the biocompatible marker is suitable for implantation for localization of an area of pathological interest. The detector is capable of detecting a response magnetic field in said biocompatible marker.
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
A61B 34/20 - Systèmes de navigation chirurgicaleDispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p. ex. pour la stéréotaxie sans cadre
A61L 31/18 - Matériaux au moins partiellement opaques aux rayons X ou au laser
A61L 31/12 - Matériaux composites, c.-à-d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent
A series of printed children's books; printed children's activity books Children's multiple activity toys; board games; educational toys in the nature of precut felt shapes, felt boards, and felt images for visual learning and imaginative play; memory games; play mats for the purpose of putting together puzzles; soft toys in the form of animals; plush toys; stuffed toy animals; and trading cards for games Online retail store services featuring subscription boxes containing children's books, children's games, toothbrushes, bath crayons, night lights, bath mits, stickers, and a postcard for parents and caregivers in the field of social emotional intelligence; Online retail store services featuring children's books, children's activity books, children's toys, board games, educational toys in the nature of precut felt shapes, felt boards, and felt images for visual learning and imaginative play, memory games, play mats for the purpose of putting together puzzles, soft toys in the form of animals, plush toys, stuffed toy animals, and trading cards for games
A series of printed children's books; printed children's activity books Children's multiple activity toys; board games; educational toys in the nature of precut felt shapes, felt boards, and felt images for visual learning and imaginative play; memory games; play mats for the purpose of putting together puzzles; soft toys in the form of animals; plush toys; stuffed toy animals; and trading cards for games Online retail store services featuring subscription boxes containing children's books, children's games, toothbrushes, bath crayons, night lights, bath mits, stickers, and a postcard for parents and caregivers in the field of social emotional intelligence; Online retail store services featuring children's books, children's activity books, children's toys, board games; Online retail store services featuring educational toys in the nature of precut felt shapes, felt boards, and felt images for visual learning and imaginative play, memory games, play mats for the purpose of putting together puzzles, soft toys in the form of animals, plush toys, stuffed toy animals, and trading cards for games
Educational kits for children in the field of social emotional intelligence comprised primarily of children's books, children's games, toothbrushes, bath crayons, night lights, bath mitts, stickers and printed postcards for parents and caregivers, sold as a unit therewith. Online retail store services featuring subscription boxes containing children's books, children's games, toothbrushes, bath crayons, night lights, bath mits, stickers, and a postcard for parents/caregivers in the field of social emotional intelligence
27.
SMALL MOLECULES TARGETING THE VDAC NADH-BINDING POCKET TO MODULATE CANCER METABOLISM
The present invention relates to VD AC-targeting small molecules that induce mitochondrial dysfunction and inhibit cell proliferation for the treatment of, for example, cancer.
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
28.
COMPOSITIONS AND METHODS FOR MODULATING NUCLEAR ENRICHED ABUNDANT TRANSCRIPT 1 TO TREAT COGNITIVE IMPAIRMENT
The invention provides compositions for modulating the level of Neat1 IncRNA and methods of using the compositions for treating neurodegenerative diseases or disorders.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c.-à-d. autres que le ribose ou le 2'-désoxyribose
A61K 31/7125 - Acides nucléiques ou oligonucléotides ayant des liaisons internucléosides modifiées, c.-à-d. autres que des liaisons 3'-5' phosphodiester
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C12N 15/12 - Gènes codant pour des protéines animales
29.
Use of Caveolin-1 Scaffolding Domain Peptides for Treating Disease and Disorders
Disclosed are CSD domain peptides and methods of use to treat diseases and disorders including fibrosis, diseases or disorders involving microvascular leakage, kidney disease, heart disease, and age-related diseases or disorders.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
An expandable vertebral body device, system, instrument, and methods of assembly and using the device, system, and instrument are disclosed. The vertebral body device includes a body with a first end and a second end, a first rotating member rotatably coupled to the first end, a second rotating member rotatably coupled to the second end, a first extension member moveably coupled to the first end, and a second extension member moveably coupled to the second end. The expandable cage system comprises a vertebral body device and an insertion instrument. Methods for assembling and using the vertebral body device and instrument are also disclosed.
Provided are methods for reducing substance consumption by subjects. In some embodiments, the presently disclosed methods include administering to a subject in need thereof a composition that includes an effective amount of an inhibitor of an EHMT2/G9A biological activity. In some embodiments, the inhibitor of an EHMT2/G9A biological activity is a small molecule inhibitor, a nucleic acid-based inhibitor, and anti-EHMT2/G9A antibody or a fragment or derivative thereof, or any combination thereof. Also provided are methods for reducing relapse vulnerability in subjects that have Alcohol Use Disorder (AUD) and/or another substance use disorder. In some embodiments, the presently disclosed methods further include administering at least one additional therapy to subjects, including but not limited to behavioral therapies such as cognitive behavioral therapies.
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
The present invention relates to systems for providing noninvasive cranial nerve stimulation and methods for using the same. The present invention administers therapy through electrodes that are noninvasively attached to one or more of a subject’s cranial nerve. The systems can be used to enhancing rehabilitation and recovery by improving neuroplasticity and coupling muscle training with feedback.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
The present invention relates to systems for providing noninvasive cranial nerve stimulation and methods for using the same. The present invention administers therapy through electrodes that are noninvasively attached to one or more of a subject’s cranial nerve. The systems can be used to enhancing rehabilitation and recovery by improving neuroplasticity and coupling muscle training with feedback.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
34.
Methods, systems, and computer readable media for utilizing spectral circles for magnetic resonance spectroscopy analysis
A method comprising collecting magnetic resonance imaging (MRI) scanner data corresponding to a region of interest, establishing a spectral peak profile associated with at least one metabolite in the region of interest, wherein the spectral peak profile comprises a term in the FID vector signal included in the collected MRI scanner data, selecting at least three counter indices and corresponding points on the spectral peak profile to compute a linear fractional transformation (LFT), computing an N-dimensional vector outlining a spectral circle in a complex plane by applying the LFT to each counter index included in a set of equally-spaced counter indices associated with a three-dimensional spectrum representation of the collected MRI scanner data, shifting the spectral circle to eliminate a baseline offset for a magnitude spectrum associated with the complex plane, rotating the shifted spectral circle to produce a rotated spectral circle.
G01R 33/485 - Systèmes d'imagerie RMN avec sélection de signaux ou de spectres de régions particulières du volume, p. ex. spectroscopie in vivo basés sur l'information de déplacement chimique
Described herein are methods for preventing non-insulted cell damage during a subject's exposure to radiation. In some embodiments, the method can include administering an amount of poloxamer 188 or a pharmaceutical formulation thereof to a subject prior to exposure to an insult.
A televisual field system for assessing neurological performance of a patient is described. The system includes a headset having a display and a sensor, an assessment module, and a controller communicatively coupled to the display, sensor and assessment module. The controller is configured to send a signal to the display to initiate a visual effect indicative of a threat to the patient, receive a measurement signal from the sensor indicative of patient response to the threat, and determine a blink-to-threat response based on an elapsed time between the visual effect and the patient response. A method for assessing neurological performance of a patient is also described.
A61B 5/16 - Dispositifs pour la psychotechnieTest des temps de réaction
A61B 3/10 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
37.
CLOSED-LOOP SIMULTANEOUS FUNCTIONAL MAGNETIC RESONANCE IMAGING (fMRI)-ELECTROENCEPHALOGRAM (EEG)-TRANSCRANIAL MAGNETIC STIMULATION (TMS) SYSTEM
The present subject matter relates to techniques for systems and methods for determining alpha phase in brain of subjects undergoing depressive disorder. The disclosed system for a closed-loop operation in simultaneous functional magnetic resonance imaging (fMRI)-electroencephalogram (EEG)-transcranial magnetic stimulation (TMS), can include a processor that be configured to receive and process a functional magnetic resonance imaging (fMRI) data and/or an extracranial electroencephalogram (EEG) data and/or transcranial magnetic stimulation (TMS) pulse simultaneously.
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
A61N 2/02 - Magnétothérapie utilisant des champs magnétiques produits par des bobines, y compris par des boucles à spire unique ou par des électro-aimants
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
38.
GLYCOPROTEIN A REPETITIONS PREDOMINANT (GARP)-BINDING ANTIBODIES AND USES THEREOF
Isolated or recombinant monoclonal antibodies that bind to GARP are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. Further provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of an anti-platelet agent and a T cell therapy.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
C07K 16/34 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des antigènes de groupes sanguins
39.
GLYCOPROTEIN A REPETITIONS PREDOMINANT (GARP)-BINDING ANTIBODIES AND USES THEREOF
Isolated or recombinant monoclonal antibodies that bind to GARP are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. Further provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of an anti-platelet agent and a T cell therapy.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
C07K 16/34 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des antigènes de groupes sanguins
40.
SYSTEMS AND METHODS FOR DETECTING MOTONEURON EXCITABILITY
The present disclosure describes devices and methods for detecting motoneuron excitability in a subject in need. The method includes stimulating a cutaneous distribution of a patient’s vagus nerve within a patient’s ear with a nerve stimulating signal; detecting F-wave occurrence with an evoked electromyography paradigm; and adjusting one or more parameters of the nerve stimulating signal to change the F-wave occurrence.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
University of Florida Research Foundation, Inc. (USA)
The United States Government as Represented by the Department of Veterans Affairs (USA)
Inventeur(s)
Vetter, Monica
Bosco, Alejandra
Rohrer, Baerbel
Tomlinson, Stephen
Hauswirth, William W.
Abrégé
Recombinant vectors operably encoding a CR2-FH fusion protein comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising the recombinant vector, are described. Also provided are methods of using the compositions for treatment eye diseases such as macular degeneration or glaucoma.
The present invention relates to compounds of formula (I): including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, hypercholesterolemia.
The present invention relates to compounds of formula (I): including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, hypercholesterolemia.
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
43.
ENDOSTATIN PEPTIDES FOR THE TREATMENT OF TUMORS, FIBROSIS AND ACUTE LUNG INJURY
The present invention provides compositions and methods for treatment or prevention of tumor growth, fibrosis, acute lung injury or a combination thereof. In one embodiment, the composition comprises a peptide derived from the C -terminal region of endostatin.
A cranial anchor system configured to attach to an opening in a cranium includes an anchor member. The anchor member has a middle anchor portion and a lower anchor portion coupled to and disposed in a downward direction relative to the middle anchor portion. The lower anchor portion has a plurality of contact members, each of which have a leg that extends at least partially in the downward direction, a tab connected to the leg, and a rib disposed between the leg and the tab. The system further includes an outer sheath and an inner sheath disposed within the outer sheath and slidable relative to the outer sheath.
A61B 90/10 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures pour la chirurgie stéréotaxique, p. ex. système stéréotaxique à cadre
45.
SELECTIVE TARGETING OF CD38 ACTIVITY AS AN IMMUNOSTIMULATORY AND ANTITUMOR STRATEGY
The present invention relates compounds having the general structure of formulas I and II, and other compounds having similar activity, including any pharmaceutically acceptable salts thereof. The invention includes the use of such compounds for the treatment of diseases, for example, for the treatment of cancer.
C07D 417/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
The present invention provides compositions and methods for treatment or prevention of tumor growth, fibrosis, acute lung injury or a combination thereof. In one embodiment, the composition comprises a peptide derived from the C -terminal region of endostatin.
The present invention relates to an adoptive T cell therapy using cells generated by genetically or biochemically reprogramming T cells to produce T memory stem cells (Tscm) that persist longer in vivo and are superior anti-tumor effector cells.
Described herein are compositions capable of targeting CaMKKβ and/or AMPK alpha and formulations thereof. Also described herein are methods of using the compositions and formulations thereof. In some embodiments, the compositions capable of targeting CaMKKβ and/or AMPK alpha and formulations thereof can prevent or treat outer hair cell loss, such as that which can occur as a result of auditory or chemical insult. In some embodiments, the compositions capable of targeting CaMKKβ and/or AMPK alpha and formulations thereof can treat or prevent acquired hearing loss.
The present invention provides articulating expandable devices and insertion tools for deploying the articulating expandable devices. The articulating expandable devices are capable of being inserted into narrow spaces and turning around corners. The articulating expandable devices are capable of increasing in height and width when expanded from a closed configuration to an open configuration to occupy a larger volume and to present a larger surface area. The articulating expandable devices are lockable and are capable of rigidly occupying a space after expansion. In some embodiments, the articulating expandable devices are useful as interbody devices for spinal fusions.
The present invention generally relates to compositions comprising one or more modulator of one or more chemoresistance promoting molecule, one or more chemosensitivity promoting molecule, or combination thereof, and methods of use thereof. The present invention also relates to CD44v6 inhibitor compositions and methods of use for treating or preventing one or more disease or disorder, such as cancer.
An expandable vertebral body implant, and methods of assembly and using the implant. The vertebral body implant includes a body with a first end and a second end, a rotating member rotatably coupled to the first end of the body, wherein an end includes a plurality of first notches inset into the rotating member, an extension member moveably coupled to the rotating member, and a locking member positioned on an interior of the body. Methods for assembling and using the vertebral body implant are also disclosed.
The Regents of The University of Colorado, A Body Corporate (USA)
MUSC Foundation For Research Development (USA)
Inventeur(s)
Holers, V. Michael
Thurman, Joshua M.
Kulik, Liudmila
Tomlinson, Stephen
Abrégé
The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
53.
EPIGENETIC MODERATORS OF NALTREXONE EFFICACY IN REDUCING HEAVY DRINKING IN INDIVIDUALS DIAGNOSED WITH ALCOHOL USE DISORDER
Disclosed are method for predicting naltrexone response in subjects with AUD. In some embodiments, the methods include performing or having performed one or more methylation assays on a genomic DNA sample isolated from the subject to determine the methylation status of one or more regions of the isolated genomic DNA, wherein the one or more regions are subsequences of a gene selected from a mu opioid receptor (OPRM1) gene, a catechol-O-methyltransferase (COMT) gene, and a dopamine transporter (SLC6A3) gene, wherein the methylation status of the one or more regions of the isolated genomic DNA determined is predictive of naltrexone response in the subject. Also provided are method for treating patients diagnosed with AUD with the medication naltrexone based on a methylation status of a combination of specific methylation sites located associated with an OPRM1 gene, a COMT gene, and/or an SLC6A3 gene in obtained from each AUD patient.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
54.
EPIGENETIC MODERATORS OF NALTREXONE EFFICACY IN REDUCING HEAVY DRINKING IN INDIVIDUALS DIAGNOSED WITH ALCOHOL USE DISORDER
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (USA)
Inventeur(s)
Anton, Raymond F
Schacht, Joseph P.
Abrégé
Disclosed are method for predicting naltrexone response in subjects with AUD. In some embodiments, the methods include performing or having performed one or more methylation assays on a genomic DNA sample isolated from the subject to determine the methylation status of one or more regions of the isolated genomic DNA, wherein the one or more regions are subsequences of a gene selected from a mu opioid receptor (OPRM1) gene, a catechol-O-methyltransferase (COMT) gene, and a dopamine transporter (SLC6A3) gene, wherein the methylation status of the one or more regions of the isolated genomic DNA determined is predictive of naltrexone response in the subject. Also provided are method for treating patients diagnosed with AUD with the medication naltrexone based on a methylation status of a combination of specific methylation sites located associated with an OPRM1 gene, a COMT gene, and/or an SLC6A3 gene in obtained from each AUD patient.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
A61P 25/32 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance à l'alcool
55.
EPIGENETIC MODERATORS OF NALTREXONE EFFICACY IN REDUCING HEAVY DRINKING IN INDIVIDUALS DIAGNOSED WITH ALCOHOL USE DISORDER
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (USA)
MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (USA)
Inventeur(s)
Anton, Raymond, F
Schacht, Joseph, P.
Abrégé
Disclosed are method for predicting naltrexone response in subjects with AUD. In some embodiments, the methods include performing or having performed one or more methylation assays on a genomic DNA sample isolated from the subject to determine the methylation status of one or more regions of the isolated genomic DNA, wherein the one or more regions are subsequences of a gene selected from a mu opioid receptor (OPRM1) gene, a catechol-O-methyltransferase (COMT) gene, and a dopamine transporter (SLC6A3) gene, wherein the methylation status of the one or more regions of the isolated genomic DNA determined is predictive of naltrexone response in the subject. Also provided are method for treating patients diagnosed with AUD with the medication naltrexone based on a methylation status of a combination of specific methylation sites located associated with an OPRM1 gene, a COMT gene, and/or an SLC6A3 gene in obtained from each AUD patient.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
A61P 25/32 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance à l'alcool
The present invention provides devices and systems for detecting shunt malfunction. The detection devices employ ultrasound instrumentations to evaluate shunt malfunction. The detection devices can be coupled with pumps to provide consistent shunt valve and/or reservoir actuation for reliable readings. The devices can output a determination of a degree of shunt blockage and relative location of shunt blockage.
A61M 27/00 - Appareillage pour drainage des blessures
G01F 1/663 - Mesure du débit volumétrique ou du débit massique d'un fluide ou d'un matériau solide fluent, dans laquelle le fluide passe à travers un compteur par un écoulement continu en mesurant la fréquence, le déphasage, le temps de propagation d'ondes électromagnétiques ou d'autres types d'ondes, p. ex. en utilisant des débitmètres à ultrasons en mesurant le décalage de fréquence Doppler
57.
COMPOSITIONS AND METHODS TARGETING THE NUCLEOTIDE FREE STATE OF RAS TO BLOCK ONCOGENIC SIGNALING AND TRANSFORMATION
The United States Government as Represented by the Department of Veterans Affairs (USA)
Inventeur(s)
O'Bryan, John
Koide, Shohei
Koide, Akiko
Abrégé
The invention provides compositions and methods for binding Ras in a nucleotide free state (apo RAS) and inhibiting Ras signaling. In one embodiment, the invention provides monobodies that specifically bind apo RAS and methods of use. Thus, in diseases and conditions where a reduction of Ras signaling is beneficial, such inhibitory compositions act as therapeutics.
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A system for neurorehabilitation is disclosed that includes a motion detector configured to generate a motion detection feedback signal, a transcutaneous auricular vagus nerve stimulation module, and a controller configured to receive the motion detection feedback signal and send a stimulation signal to the transcutaneous auricular vagus nerve stimulation module based on the motion detection feedback signal meeting a minimum threshold criteria. A method for neurorehabilitation is disclosed that includes the steps of detecting patient motor activity, determining if the detected patient motor activity meets a minimum threshold criteria, and stimulating a vagus nerve through transcutaneous auricular vagus nerve stimulation if the minimum threshold criteria is met.
A61N 1/32 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
Ionic conjugates of selenite anions and cationic ceramide analogs are described. For instance, conjugates can comprise ionic conjugates of selenite anions and pyridinium-substituted ceramide analogs. Also described is the use of the ionic conjugates in treating cancer, such as head and neck cancer and brain cancer.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
61.
S-NITROSOGLUTATHIONE (GSNO) AND GSNO REDUCATASE INHIBITORS FOR USE IN THERAPY
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventeur(s)
Singh, Inderjit
Singh, Avtar K.
Abrégé
The present disclosure provides methods for the treatment or prevention of SARS-Cov-2 infection or disease and IL-6 mediated immune/autoimmune and cancers by the administration of GSNO or GSNO reductase inhibitor.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/566 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
63.
Compounds for the treatment of neurological or mitochondrial diseases
Compounds and methods are provided for the treatment of neurological or mitochondrial diseases, including epilepsy. In some embodiments, the compounds are substituted 1,4-naphthoquinones.
A61K 31/136 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p. ex. benzène-amine
The invention relates to KDM4B inhibitors, compositions comprising an effective amount of KDM4B inhibitors and methods for treating inflammatory diseases and disorders.
C07C 235/38 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone acycliques et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné le squelette carboné contenant des cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un cycle aromatique à six chaînons
65.
CRANIAL ANCHORING AND POSITIONING SYSTEM AND METHOD
A cranial anchor system configured to attach to an opening in a cranium includes an anchor member. The anchor member has a middle anchor portion and a lower anchor portion coupled to and disposed in a downward direction relative to the middle anchor portion. The lower anchor portion has a plurality of contact members, each of which have a leg that extends at least partially in the downward direction, a tab connected to the leg, and a rib disposed between the leg and the tab. The system further includes an outer sheath and an inner sheath disposed within the outer sheath and slidable relative to the outer sheath.
A61B 90/10 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures pour la chirurgie stéréotaxique, p. ex. système stéréotaxique à cadre
A61B 90/11 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures pour la chirurgie stéréotaxique, p. ex. système stéréotaxique à cadre avec des guides pour aiguilles ou instruments, p. ex. des glissières courbes ou des articulations à rotule
66.
METHODS, SYSTEMS, AND COMPUTER READABLE MEDIA FOR UTILIZING SPECTRAL CIRCLES FOR MAGNETIC RESONANCE SPECTROSCOPY ANALYSIS
A method comprising collecting magnetic resonance imaging (MRI) scanner data corresponding to a region of interest, establishing a spectral peak profile associated with at least one metabolite in the region of interest, wherein the spectral peak profile comprises a term in the FID vector signal included in the collected MRI scanner data, selecting at least three counter indices and corresponding points on the spectral peak profile to compute a linear fractional transformation (LFT), computing an N-dimensional vector outlining a spectral circle in a complex plane by applying the LFT to each counter index included in a set of equally-spaced counter indices associated with a three- dimensional spectrum representation of the collected MRI scanner data, shifting the spectral circle to eliminate a baseline offset for a magnitude spectrum associated with the complex plane, rotating the shifted spectral circle to produce a rotated spectral circle.
G01R 33/485 - Systèmes d'imagerie RMN avec sélection de signaux ou de spectres de régions particulières du volume, p. ex. spectroscopie in vivo basés sur l'information de déplacement chimique
67.
G9A INHIBITION DECREASES STRESS-INDUCED AND DEPENDENCE-INDUCED ESCALATION OF ALCOHOL DRINKING
Provided are methods for reducing substance consumption by subjects. In some embodiments, the presently disclosed methods include administering to a subject in need thereof a composition that includes an effective amount of an inhibitor of an EHMT2/G9A biological activity. In some embodiments, the inhibitor of an EHMT2/G9A biological activity is a small molecule inhibitor, a nucleic acid-based inhibitor, and anti-EHMT2/G9A antibody or a fragment or derivative thereof, or any combination thereof. Also provided are methods for reducing relapse vulnerability in subjects that have Alcohol Use Disorder (AUD) and/or another substance use disorder. In some embodiments, the presently disclosed methods further include administering at least one additional therapy to subjects, including but not limited to behavioral therapies such as cognitive behavioral therapies.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire
Described herein are methods for preventing non-insulted cell damage during a subject's exposure to radiation. In some embodiments, the method can include administering an amount of poloxamer 188 or a pharmaceutical formulation thereof to a subject prior to exposure to an insult.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
69.
USE OF CAVEOLIN-1 SCAFFOLDING DOMAIN PEPTIDES FOR TREATING DISEASE AND DISORDERS
Disclosed are CSD domain peptides and methods of use to treat diseases and disorders including fibrosis, diseases or disorders involving microvascular leakage, kidney disease, heart disease, and age-related diseases or disorders.
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 38/03 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés
A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
70.
BI-FUNCTIONAL ARGININE-GLYCINE-ASPARTIC ACID (RGD) PEPTIDES AND METHODS TO PROMOTE ANGIOGENESIS
The present invention provides an in vitro method for identifying a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation for the manufacture of a diagnostic or therapeutic agent. The present invention further provides the identified compounds and pharmaceutical compositions, and assays and kits for identifying a compound or using a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation and is useful for bioprinting.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
G01N 33/74 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des hormones
C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
C07K 17/02 - Peptides immobilisés sur, ou dans, un support organique
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
Provided herein is a pharmaceutical combination comprising SFRP2 antagonist and an PD-1 antibody antagonist. The invention also provides a method for the treatment of cancer, comprising the administration of a therapeutically effective amounts of a SFRP2 antagonist and a PD-1 antagonist to a patient in need thereof.
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A declogging assembly (20) is configured for use with a suction conduit (10). The suction conduit has a head (14) at a first end (15) and a vacuum tube connection (16) at a second end (17). The assembly includes a body (30). The body defines a first aperture (32), a second aperture (34), and a third aperture (36). The assembly also includes a plug (40) disposed within the body (30). The plug has a surface (42) configured to contact the head (14) of the suction conduit (10) so as to move the plug from a first position, in which the first aperture (32) is in fluid communication with the second aperture (34), to a second position, in which the first aperture (32) is in fluid communication with the third aperture (36). The assembly (20) also includes a biasing member (50) configured to bias the plug into the first position.
A61C 17/06 - Appareils pour enlever la saliveLeurs accessoires
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
A61B 90/70 - Dispositifs de nettoyage spécialement adaptés aux instruments chirurgicaux
73.
Compositions and methods for treating central nervous system injury
United States Government as Represented by the Department of Veteran Affairs (USA)
Inventeur(s)
Tomlinson, Stephen
Adkins, Deanna
Alawieh, Ali
Abrégé
The present invention describes compositions and method for improving outcomes after injury to the central nervous system wherein complement signaling is activated. In one aspect, the method comprises administering to a subject a therapeutically effective amount of a therapeutic agent comprising a targeted inhibitor molecule comprising a targeting portion and an inhibitor portion, wherein the molecule inhibits complement, and wherein therapeutic agent is administered in combination with rehabilitation therapy or thrombolytic agent.
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 38/57 - Inhibiteurs de protéases provenant d'animauxInhibiteurs de protéases provenant d'humains
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
The present invention relates to systems for providing noninvasive cranial nerve stimulation and methods for using the same. The present invention administers therapy through electrodes that are noninvasively attached to one or more of a subject's cranial nerve. The systems can be used to enhancing rehabilitation and recovery by improving neuroplasticity and coupling muscle training with feedback.
The invention provides a method for detecting an IgA anti-nuclear autoantibody in a fecal sample from a subject, wherein the presence of the IgA anti-nuclear autoantibody is an early indicator of the presence or increased risk of development of an autoimmune disease or disorder.
G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
The present invention provides minimally invasive subdural evacuating systems and methods of use thereof. The subdural evacuating systems include a cutting component and a rod component, wherein the rod component provides an external physical indicator that the surface of the dura mater has been reached, permitting the cutting component to accurately pierce the dura mater with minimal to no risk of damaging any adjacent anatomy.
Described herein are compounds, compositions, and reagents capable of labeling a biomolecule. In some embodiments, the compounds, compositions, and reagents allow for labeling to occur using a bioorthagonal reaction outside of a living cell and without a glycosyltransferase enzyme. Also described herein are methods of using the compounds compositions and reagents described herein.
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
78.
Cranial anchoring and positioning system and method
A cranial anchor system configured to attach to an opening in a cranium includes an anchor member. The anchor member has a middle anchor portion and a lower anchor portion coupled to and disposed in a downward direction relative to the middle anchor portion. The lower anchor portion has a plurality of contact members, each of which have a leg that extends at least partially in the downward direction, a tab connected to the leg, and a rib disposed between the leg and the tab. The system further includes an outer sheath and an inner sheath disposed within the outer sheath and slidable relative to the outer sheath.
A61B 90/10 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures pour la chirurgie stéréotaxique, p. ex. système stéréotaxique à cadre
79.
EXPANDABLE VERTEBRAL BODY REPLACEMENT DEVICE AND METHOD
An expandable vertebral body implant, and methods of assembly and using the implant. The vertebral body implant includes a body with a first end and a second end, a rotating member rotatably coupled to the first end of the body, wherein an end includes a plurality of first notches inset into the rotating member, an extension member moveably coupled to the rotating member, and a locking member positioned on an interior of the body. Methods for assembling and using the vertebral body implant are also disclosed.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERAN AFFAIRS (USA)
Inventeur(s)
Oates, James
Buie, Joy, Jones
Abrégé
The present invention provides compositions and methods for increasing nitric oxide production for treating or preventing a chronic inflammatory autoimmune disease or disorder.
The United States Government as Represented by the Department of Veterans Affairs (USA)
Inventeur(s)
Lindsey, Christopher C.
Beeson, Craig C.
Peterson, Yuri Karl
Schnellmann, Rick G.
Abrégé
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, promote mitochondrial biogenesis and are useful for the treatment of, for example, acute kidney injury and chronic kidney disease.
Microparticles comprising arsenic trioxide (ATO) microcrystals and biocompatible polymers and their related pharmaceutical formulations are described. The microparticles and their formulations can be used as chemoembolization agents, for example, as transarterial chemoembolization agents. Also described are related methods of preparing the microparticles and methods of treating tumors, such as liver tumors or tumors that have metasatized to the liver, by administration of the microparticles.
The present invention provides expandable devices and insertion tools for deploying the expandable devices. The expandable devices are capable of increasing in height and width when expanded from a closed configuration to an open configuration to occupy a larger volume and to present a larger surface area. The expandable devices are lockable and are capable of rigidly occupying a space after expansion. In some embodiments, the expandable devices are useful as interbody devices for spinal fusions.
The present invention relates to compounds of formula (I) : including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, hypercholesterolemia.
The present invention relates to compounds of formula (I) : including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, hypercholesterolemia.
The present invention relates to systems for providing noninvasive cranial nerve stimulation and methods for using the same. The present invention administers therapy through electrodes that are noninvasively attached to one or more of a subject's cranial nerve. The systems can be used to enhancing rehabilitation and recovery by improving neuroplasticity and coupling muscle training with feedback.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
The present invention provides methods and compositions for glycan analysis of complex solutions, including proteins and cells in a biological sample. The method includes the preparation of substrates for the capture of proteins and cells for multiplexed analysis. Cells and proteins may be captured by antibody arrays, culture, or direct deposition. The invention further relates to the use of protein and cell glycan analysis in the diagnosis and screening of disease states and disease progression.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
The present disclosure provides a recombinant oncolytic virus engineered to express a soluble form of an immune checkpoint protein. In certain aspects, the oncolytic vims is a replication competent virus such as myxoma vims. Methods of cancer treatment comprising administering the recombinant oncolytic virus expressing the soluble form of the immune checkpoint protein are also provided.
The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
90.
RNAI-BASED TARGETING COMPOUNDS AND USES THEREOF TO PREVENT ACQUIRED HEARING LOSS
Described herein are compositions capable of targeting CaMK/Κβ and/or AMPK alpha and formulations thereof. Also described herein are methods of using the compositions and formulations thereof. In some embodiments, the compositions capable of targeting CaMK/Κβ and/or AMPK alpha and formulations thereof can prevent or treat outer hair cell loss, such as that which can occur as a result of auditory or chemical insult. In some embodiments, the compositions capable of targeting CaMK/Κβ and/or AMPK alpha and formulations thereof can treat or prevent acquired hearing loss.
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Arranging and conducting of educational conferences in the field of telehealth; Educational services, namely, developing, arranging, and conducting educational conferences and programs and providing courses of instruction in the field of telehealth Developing accreditation standards for telehealth services to the order and specification of others
92.
T regulatory (Treg) cell transplantation in osteogenesis imperfecta (OI)
The present invention relates to compositions comprising induced T regulatory cells (iTregs), methods of making the compositions, and methods of using the compositions for enhancing bone remodeling in the treatment of Osteogenesis Imperfecta (OI).
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 19/08 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
93.
Needle electrode fixation device and associated methods
A needle electrode fixation device is configured to secure a transdermal needle electrode to a patient. The device includes a base having a body that defines a first portion and a second portion. The first and second portions are rotatable relative to each other. The first portion defines a channel configured to fit a portion of the transdermal needle electrode. The second portion defines a recess configured to fit a tip of the needle electrode. The device further includes an adhesive layer configured to affix the base to the patient.
The present invention provides devices and systems for detecting shunt malfunction. The detection devices employ ultrasound instrumentations to evaluate shunt malfunction. The detection devices can be coupled with pumps to provide consistent shunt valve and/or reservoir actuation for reliable readings. The devices can output a determination of a degree of shunt blockage and relative location of shunt blockage.
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
Ionic conjugates of selenite anions and cationic ceramide analogs are described. For instance, conjugates can comprise ionic conjugates of selenite anions and pyridinium-substituted ceramide analogs. Also described is the use of the ionic conjugates in treating cancer, such as head and neck cancer and brain cancer.
The present invention provides decorticating screws and insertion tools for implanting the decorticating screws. The screws anchor into a first and a second bone to fuse the two bones together. The screws include a rotatable bladed section to decorticate a joint space between the first and second bone. The screws also optionally include a cap to secure the screws in the bone and apply compression to the joint to be fused. In some embodiments, the decorticating screws are useful for sacroiliac (SI) joint fusion.
A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
A61B 17/16 - Instruments pour réaliser une ostéoclasieForets ou ciseaux pour osTrépans
A61B 17/58 - Instruments ou procédés chirurgicaux pour le traitement des os ou des articulationsDispositifs spécialement adaptés à cet effet pour ostéosynthèse, p. ex. plaques, vis ou matériels de fixation
The present-invention provides compositions and methods for treatment or prevention of tumor growth, fibrosis, acute lung injury or a combination thereof. In one embodiment, the composition comprises a peptide derived from the C-terminal region of endostatin. Further provides are amino acid sequences of the peptides derived from the C-terminal region of endostatin.
The present invention provides minimally invasive subdural evacuating systems and methods of use thereof. The subdural evacuating systems include a cutting component and a rod component, wherein the rod component provides an external physical indicator that the surface of the dura mater has been reached, permitting the cutting component to accurately pierce the dura mater with minimal to no risk of damaging any adjacent anatomy.
